Medicis Pharmaceutical Corp. (NYSE: MRX) may face competition for its acne drug after the FDA rejected a petition to block generic copies made by Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA). Shares of Medicis tumbled $1.42 while Teva stock eased 49 cents to $45.17.
Medicis Faces Generic Competition
March 18, 2009 at 13:28 PM EDT
